Vaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by Comerica Bank

Comerica Bank lifted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 0.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 188,084 shares of the company’s stock after acquiring an additional 246 shares during the quarter. Comerica Bank owned 0.17% of Vaxcyte worth $12,848,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in PCVX. Arizona State Retirement System increased its stake in shares of Vaxcyte by 4.9% during the fourth quarter. Arizona State Retirement System now owns 20,988 shares of the company’s stock worth $1,318,000 after acquiring an additional 977 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Vaxcyte by 0.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock worth $3,211,000 after buying an additional 296 shares during the period. Allspring Global Investments Holdings LLC grew its position in Vaxcyte by 1,005.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 22,603 shares of the company’s stock worth $1,419,000 after buying an additional 20,558 shares during the period. Moody Aldrich Partners LLC lifted its holdings in shares of Vaxcyte by 5.5% in the fourth quarter. Moody Aldrich Partners LLC now owns 147,927 shares of the company’s stock valued at $9,290,000 after purchasing an additional 7,757 shares in the last quarter. Finally, Mutual of America Capital Management LLC purchased a new stake in shares of Vaxcyte in the fourth quarter valued at about $3,035,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on PCVX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th. Needham & Company LLC reissued a “buy” rating and set a $95.00 price objective on shares of Vaxcyte in a research note on Friday, June 28th.

Insider Transactions at Vaxcyte

In other news, Director Halley E. Gilbert sold 18,200 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $1,328,600.00. Following the completion of the sale, the director now owns 5,625 shares of the company’s stock, valued at $410,625. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $74.99, for a total value of $599,920.00. Following the transaction, the chief financial officer now directly owns 95,679 shares in the company, valued at approximately $7,174,968.21. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Halley E. Gilbert sold 18,200 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $1,328,600.00. Following the completion of the transaction, the director now owns 5,625 shares in the company, valued at $410,625. The disclosure for this sale can be found here. Insiders sold 103,766 shares of company stock valued at $7,923,441 over the last 90 days. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

NASDAQ:PCVX traded up $0.13 during trading hours on Thursday, reaching $79.02. 294,773 shares of the company were exchanged, compared to its average volume of 785,265. The firm has a market cap of $8.60 billion, a price-to-earnings ratio of -18.43 and a beta of 0.97. Vaxcyte, Inc. has a 52-week low of $44.20 and a 52-week high of $87.71. The stock has a 50 day simple moving average of $76.29 and a 200 day simple moving average of $71.09.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.28. On average, analysts predict that Vaxcyte, Inc. will post -3.93 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.